Lundbeck will buy Longboard Pharmaceuticals and its 5-HT 2C receptor agonist bexicaserin, which is currently in phase III development for seizures associated with Dravet syndrome. The deal, valued at ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...

LA JOLLA, Calif., November 12, 2024--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

Oct 14 (Reuters) - H Lundbeck A/S (HLUNb.CO), opens new tab has agreed to buy U.S.-based Longboard Pharmaceuticals (LBPH.O), opens new tab for $2.6 billion, marking the biggest deal ever by the Danish ...